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ABSTRACT
The existence of tissue-speciﬁc progenitor/stem cells in the adult pituitary gland of the mouse
has been demonstrated recently using genetic tracing experiments. These cells have the capacity
to differentiate into all of the different cell lineages of the anterior pituitary and self-propagate
in vitro and can therefore contribute to normal homeostasis of the gland. In addition, they play
a critical role in tumor formation, speciﬁcally in the etiology of human adamantinomatous cra-
niopharyngioma, a clinically relevant tumor that is associated with mutations in CTNNB1 (gene
encoding b-catenin). Mouse studies have shown that only pituitary embryonic precursors or
adult stem cells are able to generate tumors when targeted with oncogenic b-catenin, suggest-
ing that the cell context is critical for mutant b-catenin to exert its oncogenic effect. Surpris-
ingly, the bulk of the tumor cells are not derived from the mutant progenitor/stem cells,
suggesting that tumors are induced in a paracrine manner. Therefore, the cell sustaining the
mutation in b-catenin and the cell-of-origin of the tumors are different. In this review, we will
discuss the in vitro and in vivo evidence demonstrating the presence of stem cells in the adult
pituitary and analyze the evidence showing a potential role of these stem cells in pituitary
tumors. STEM CELLS 2016; 00:000—000
SIGNIFICANCE STATEMENT
In this concise review, we aim to discuss the accumulated evidence suggesting the presence of
PSCs within the adult pituitary gland and the potential role of these cells in normal organ
homeostasis. Additionally, we will elaborate on the data supporting the existence of CSCs in
human and mouse tumours with particular emphasis to the role of pituitary PSCs in the aetiol-
ogy of human craniopharyngioma.
INTRODUCTION
In recent years, solid evidence has emerged
for the existence of a tissue-speciﬁc population
of undifferentiated progenitors or stem cells
within the hormone-secreting anterior pituitary
gland (pituitary stem cells, PSCs). These long-
lived, undifferentiated cells have the capacity
to directly commit or generate daughter cells
of three main progenitor lineages, character-
ized by respective expression of three tran-
scription factors, PIT1 (POU1F1), TPIT (TBX19),
and SF1 (NR5A1). Expression of these factors
is a necessary step toward differentiation into
a hormone-secreting cell in the pituitary,
where: PIT1-positive cells give rise to GH-
expressing somatotrophs, PRL-expressing lacto-
trophs, and TSH-expressing thyrotrophs (PIT1-
cell lineage); TPIT-positive cells give rise to
ACTH-expressing adrenocorticotrophs and mel-
anotrophs; and ﬁnally, SF1-positive cells give
rise to LH- and FSH-expressing gonadotrophs.
The precise regulation of these populations
ensures effective homeostasis and is dynamic
throughout life, largely dependent on physio-
logical demand. This can also be inﬂuenced by
damage to pituitary tissue or to any of its tar-
get endocrine organs, and can be affected dur-
ing disease states.
Similar to organ-speciﬁc stem cells, analy-
ses of many tumors and cancers have revealed
the presence of multipotent cells, often
thought to drive tumor formation. Conceptu-
ally, cancer stem cells (CSCs) are characterized
by two features: (a) self-renewal and (b) capa-
bility to generate the mass of the tumor/can-
cer cells in a cell-autonomous manner (i.e., the
tumor cells are descendants of the CSCs). This
deﬁnition does not relate to their potential
origin, whether these are normal tissue-
speciﬁc somatic stem cells, progenitors or dif-
ferentiated cells. Experimentally, CSCs are
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determined by the identiﬁcation of speciﬁc cells able to prop-
agate a tumor/cancer and replicate its cellular composition in
a relevant experimental setting, ideally in situ, either by line-
age tracing or orthotopic transplantation. These have been
isolated from leukemia and solid tumors [1–5]. Generally,
CSCs represent a small population of the tumor mass but are
able to drive tumorigenesis when transplanted into a host,
usually immunosuppressed mice (e.g., nonobese diabetic/
severe combined immunodeﬁciency [NOD/SCID] mouse) [6].
CSCs are endowed with molecular and cellular properties that
make them particularly resistant to common anti-cancer
agents and radiotherapy [7, 8]. They are often, although not
necessarily, slow cycling or quiescent (nondividing) cells [9],
and therefore antiproliferative agents or radiotherapy have lit-
tle or no effect despite causing shrinking of the tumor mass
[10]. Similarly, CSCs express high levels of proteins that confer
resistance to cytotoxic compounds such as anti-cancer drugs
(e.g., ABC transporters, and aldehyde dehydrogenase) [11]. It
is generally thought that effective anti-cancer therapies
should aim to eliminate the bulk of the tumor cells as well as
the resident CSCs.
Many of the properties of CSCs are shared by normal
tissue-speciﬁc stem cells; slow cycling status, self-renewal, and
differentiation capacity and even resistance to cytotoxic drugs.
For some tumors, it has been shown that normal stem cells
are transformed into CSCs when targeted to express onco-
genic proteins. For instance, stem cells of the intestinal crypt
become CSCs when the WNT/b-catenin pathway is over-
activated [12, 13]. However, progenitor cells or even differen-
tiated cells could give rise to CSCs upon oncogenic transfor-
mation [6, 14].
In this concise review, we aim to discuss the accumulated
evidence suggesting the presence of PSCs within the adult
pituitary gland and the potential role of these cells in normal
organ homeostasis. Additionally, we will elaborate on the data
supporting the existence of CSCs in human and mouse tumors
with particular emphasis to the role of pituitary PSCs in the
etiology of human craniopharyngioma. For more detailed dis-
cussion, we refer the reader to other recent reviews [15–19]
CELLULAR AND MOLECULAR PROPERTIES OF PSCS
Two initial studies revealed postnatal mouse pituitary popula-
tions with in vitro self-renewal capabilities; one population
was shown capable of forming adherent colonies, and was
characterized by the uptake of the ﬂuorescent dipeptide b-
Ala-Lys-N e AMCA (AMCA is 7-amino-4-methylcourmarin-3-
acetic acid) and included cells expressing S100 calcium-
binding protein B (S100b) [20], which have been described as
folliculostellate cells of the anterior lobe [21]. The other popu-
lation was shown to form nonadherent spheres under clonal
conditions in culture and characterized by marker expression
relevant to stem cells of other tissues: expression of Sca1,
Oct4, and Nanog [22]. The same group later showed that cells
within this population were enriched for SOX2, SOX9, CD44,
and CD133 [23]. These cells had the capacity to efﬂux the
vital dye Hoechst 33342, mainly through ABC transporter
function, generating a “side population” during ﬂow cytome-
try. This is typical of many cell types with stem/progenitor
properties and the side population has been described for
pituitaries of other vertebrates [22, 24, 25]. Since these early
characterizations, many additional markers of cells with in
vitro clonogenic capacity (another characteristic of stem cells)
have been proposed, such as Nestin, PROP1, SOX9, GFRa2,
and PRX1/2 [26–30]. The transcription factor SOX2 is highly
associated with pluripotency in the early embryo, in embry-
onic stem cells (ESCs) and induced pluripotent stem cells
(iPSCs), as well as the stem cell state in multiple embryonic
and adult tissues. In the pituitary, it was shown to deﬁne a
population, which exclusively contains cells capable of both
adherent and nonadherent clonogenic colony formation (Fig.
1) [31, 32]. In vivo in the postnatal rodent gland, SOX2-
positive cells show a high degree of overlap with other pro-
posed stem cell markers such as PROP1 [27, 33], PRX1/2 [30],
and SOX9 [28].
Although SOX2-positive cells do not express any hormone
and SOX2 expression does not overlap with expression of the
committed progenitor markers, the population has a heteroge-
neous nature in terms of properties, where only a low propor-
tion (2.5%–5%) are shown to be capable of in vitro self-
renewal. This suggests that perhaps not all SOX2-positive cells
in the pituitary have stem cell capacity, or that our current
assay methodologies select a subpopulation, perhaps at a par-
ticular primed state or phase of the cell cycle, and maybe the
remainder of the SOX2-positive cells would ﬂourish under
alternative conditions. Both cases highlight the need for better
marker characterization, whose overlapping combination would
possibly deﬁne the true pituitary stem cell, poised for activa-
tion. Purifying pituitary cells based on S100b expression using
S100b-GFP transgenic animals enriches in vitro colony forma-
tion, a property lying exclusively within the SOX2-positive com-
ponent [34], hence suggesting that the overlapping population
is likely to be enriched in stem cells and the strong association
of S100b with multiple proposed pituitary stem cell popula-
tions makes this protein a good candidate marker. Indeed,
there is signiﬁcant overlap between SOX2 and S100b positivity
[31, 34] (Fig. 1). On its own, S100b marks multiple popula-
tions, displaying expression in the SOX2-positive marginal zone
region, in the morphologically distinct folliculostellate cells and
reported to be expressed in pituicytes. In rat, at least two dis-
tinct S100b populations have been isolated, one with proc-
esses typical of folliculostellate cells, which is positive for GFAP
and vimentin and a second, morphologically rounded cell type
lacking processes, which express dendritic markers [35]. Multi-
ple functions have been put forward for S100b-positive follicu-
lostellate cells reviewed comprehensively elsewhere [36],
including providing structural support and enabling communi-
cation within the pituitary facilitating pulsatile hormone secre-
tion [37, 38]. A further attribute of these cells is the
production of paracrine signals that contribute to the regula-
tion of surrounding endocrine cells. For example, synthesis
and secretion of FSH in gonadotrophs is mediated by activin,
and regulated by the activin-binding protein follistatin, both of
which are produced by folliculostellate cells [39]. Numerous
other paracrine factors secreted by these cells have been iden-
tiﬁed, including interleukin-6 (IL-6), leukemia inhibitory factor
(LIF), vascular endothelial growth factor (VEGF), and basic
ﬁbroblastic growth factor (bFGF), all of which contribute to
pituitary function [40–42].
The location of cells expressing SOX2/S100b has also been
proposed to enable stem cell function. The marginal zone,
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lining the remnants of Rathke’s pouch lumen, retains an epi-
thelium of SOX21 cells on either side. Additionally, SOX21
cells are found in the parenchyma of the anterior pituitary,
often in groups distributed among hormone-secreting cells
(Fig. 1). The in vitro clonogenic potential of SOX2 cells does
not differ between the two locations [35] and it has been
postulated that these cells form a network spanning the
whole pituitary, making connections through their projections
[43]. Recent studies from rat have revealed that SOX21/
S100b1 double-expressing cells include a further subset that
express the gene Cxadr in vivo, which codes for coxsackievirus
and adenovirus receptor (CAR), that facilitates formation of
homophilic tight junctions [44]. Furthermore, expression of E-
cadherin and the juxtacrine factor ephrin-B2 reportedly deﬁne
SOX21/S100b1/CAR1 cells, both in the marginal epithelium
and throughout the parenchyma [44, 45]. Analysis of the side
population by the group of Vankelecom had also reported
enrichment in ephrin-B expression in this stem cell-rich com-
partment [46].
CONTRIBUTION OF STEM CELLS IN THE LONG-TERM
MAINTENANCE OF THE ANTERIOR PITUITARY
Despite a plethora of identiﬁed markers, until recently, there
was no evidence to support that pituitary stem cells function
as such in vivo. This changed with the generation of two simi-
lar genetic tools, inducible mouse strains expressing CreERT2
under the regulation of the SOX2 promoter generated by the
Hochedlinger and Martinez-Barbera/Pevny labs [34, 47]. In
these, Cre is expressed in cells expressing Sox2, but will not
be active until the administration of tamoxifen, allowing tem-
poral control of recombinase action. Although the expression
construct of these two strains is not identical, the expression
of CreERT2 faithfully reproduces that of Sox2 in both. We
used one of these mouse strains to lineage trace cells
expressing Sox2 beginning at different stages, both during ges-
tation and postnatally [34]. Similarly, the Lovell-Badge group
used the strain generated by the Hochedlinger laboratory to
trace Sox2-expressing cells from embryonic stages [28]. In all
cases, Sox2-expressing cells gave rise to all committed progen-
itor cell types (PIT1, TPIT, SF1), and thus all hormone-
secreting cells types of the anterior lobe (GH, PRL, TSH, ACTH,
LH/FSH). One limitation of this assay is that it does not distin-
guish between a multipotent population of Sox2-expressing
cells and the possibility that several oligopotent or unipotent
populations of Sox2-expressing cells exist, collectively giving
rise to all differentiated lineages. To demonstrate that the
population of SOX21 cells is not depleted, as would be
expected by transit-amplifying progenitor cells, we activated
CreERT2 in SOX21 cells by postnatal tamoxifen administration,
enabling expression of R26R-EYFP and cells were traced for 6
months. At the end of this period, descendants of SOX21 cells
were ﬂow sorted for EYFP expression and cultured to assess
clonogenic potential, a property contained only among SOX21
cells. Most of the cells with clonogenic potential were residing
in the EYFP positive fraction, suggesting that SOX2 cells are
either long-lived hence persisting after their initial labeling, or
maintained as a self-renewing pool of stem cells derived from
the originally labeled SOX21 cells. If SOX21 cells were a popu-
lation of transit amplifying cells with short-term uncommitted
proliferative potential, we would expect that this population
would become depleted and lose properties associated with
the stem cell state, such as clonogenic capacity, following
their commitment/differentiation. Complementing this, follow-
ing postnatal tamoxifen inductions we found a signiﬁcant pop-
ulation of uncommitted SOX21 and SOX91 cells up to a year
following tamoxifen administration. The above experiments
demonstrate the presence of a long-lived population that
retains pituitary stem cell properties throughout normal life.
Figure 1. Stem cells in the anterior lobe of the mouse anterior pituitary. Pituitary stem cells (PSCs) reside within the
SOX21 population (yellow cells), which in the anterior lobe are located in the marginal zone epithelium at the interface with the inter-
mediate lobe and enriched at the cleft, the lateral edges of the epithelium. SOX21 cells are additionally found throughout the anterior
lobe parenchyma. PSCs are enriched through efﬂux studies enabling isolation of a side population and are deﬁned by their clonogenic
capacity in vitro, cultured either as ﬂoating spheres or adherent colonies. A number of markers enriched in PSCs have been proposed;
some of the commonly used are summarized here. Abbreviations: IL, intermediate lobe, AL, anterior lobe, PL, posterior lobe.
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STEM CELLS FROM PITUITARY TUMORS
Several groups have reported the presence of putative CSCs
in pituitary adenomas isolated from mice and humans [18,
48–55]. The criteria for a cell to be termed a CSC are based
on some or all of the following properties: (a) self-
propagation in vitro (clonogenic potential); (b) multipotent
differentiation capacity; (c) expression of “stemness” markers;
(d) chemoresistance; (e) tumorigenic potential in transplanta-
tion experiments.
A summary of the experimental approach used is as follows
(Fig. 2): tumors are dissociated into single cell suspensions and
cultured in vitro in stem cell-promoting media, which contains
ﬁbroblast growth factor (FGF) and epidermal growth factor
(EGF) but no serum. After a few days, ﬂoating spheres emerge,
which can be passaged several times and forced to differenti-
ate into hormone-producing cells when cultured in media sup-
plemented with serum and/or hypothalamic stimulating factors
controlling anterior pituitary function, and in the absence of
growth factors. In some studies, the side population assay has
been used to purify tumor cells able to efﬂux Hoechst dye,
enriching for potential CSCs [17, 23, 56]. These resulting tumor-
derived spheres express markers associated with stemness
(e.g., Nestin, SOX2, SCA1, and CD133) and do not express dif-
ferentiation markers (e.g., growth hormone). In one study, it
has been shown that the undifferentiated cells contained in
the spheres are more resistant to chemotherapeutics than dif-
ferentiated cells [49]. These in vitro-grown spheres contain
tumor-propagating cells capable to generate tumors when
transplanted into the brain [49, 50] or under the skin [48] of
immunosuppressed mice. In one study, grafted tumors have
been proven to be serially transplantable [49].
Overall, these reports have provided evidence supporting
the existence of CSCs with tumor-propagating capacity. How-
ever, several questions remain unanswered, among them: (a)
Do CSCs arise from PSCs? PSCs and CSCs share similar proper-
ties, for instance in vitro self-propagation and differentiation
potential, and it is likely that PSCs are also chemoresistant,
since a side population that is enriched for PSCs can be puri-
ﬁed from normal mouse pituitaries using the vital dye
Hoechst efﬂux assay [23]. (b) Can CSCs generate pituitary
tumors when transplanted orthotopically in the pituitary of
host mice? Orthotopic transplantations have not been per-
formed due to technical difﬁculties. These experiments will
reveal whether CSCs can be tumorigenic in a normal pituitary
gland environment. Related to this latter question, (c) can
normal PSCs generate tumors when transplanted heterotopi-
cally in the brain? Human PSCs may be difﬁcult to obtain, but
mouse PSCs are readily available.
In our opinion, questions (b) and (c) are very relevant
because they will assess the effects of the culture conditions
and cellular microenvironment on the tumorigenic capacity of
normal PSCs and of CSCs. Although generally speaking normal
stem cells do not form tumors, the potential of tumor devel-
opment is considered as one of the risks of the use of stem
cells in regenerative medicine [57, 58]. Normal hematopoietic
stem cells do not form tumors when injected into recipient
subjects, however, the evidence for other somatic stem cells
is not as solid and there are cases where “normal donor-
derived somatic stem cells” have been found to be the origin
of cancers in transplanted human and mouse hosts [59–61].
Normal untransformed PSCs could acquire genetic or epige-
netic alterations during their culture period, which may pre-
dispose them to form tumors, as described for other stem
cells [62]. The local environment in which the stem cell
resides may also inﬂuence its tumorigenic potential. The con-
cept of how the cellular environment can affect the potential
tumorigenic effects of cells is beautifully exempliﬁed by the
capacity of normal mouse and human embryonic stem cells to
generate either teratomas, when heterotopically transplanted
into adult mouse tissues, or normal chimeric organs, when
transplanted into developing embryos [63–65].
Figure 2. Methods of cancer stem cell characterization in human pituitary adenoma. Fresh tumor tissue can be dissociated and cancer
stem cells (CSC) selected in vitro based on culture properties and marker expression. Assays to determine CSC potential are in vitro dif-
ferentiation to determine their multipotent nature for appropriate tissue lineages, assays to determine possible resistance to cytotoxic
compounds (characteristic of CSCs), and xenotransplantation into animal models where CSCs are expected to reinitiate tumor growth.
Abbreviation: CSC, cancer stem cell.
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Similarly, the expansion of clonogenic pituitary CSCs
before transplantation that has been carried out in all pub-
lished reports could select for speciﬁc cell populations present
in the tumor or even induce genetic or epigenetic changes
that could account for the tumorigenic effect described. Fresh
cell suspensions from pituitary tumors that have not been cul-
tured in vitro should also be tested in transplantation experi-
ments. In this regard, a recent report has shown how critical
the inﬂuence of the in vitro manipulations may be on the
ﬁnal outcome of the transplantations. Human glioma tumor
cells cultured in stem cell-promoting medium generate tumors
of human origin in orthotopic xenotransplantations, whilst
fresh cell suspensions induce tumors of mouse origin, suggest-
ing a paracrine inﬂuence on the host tissue [66]. Perhaps,
future mouse experiments should also address the tumori-
genic potential of “normal” PSCs when transplanted
heterotopically.
PARACRINE CONTRIBUTION OF STEM CELLS TO TUMORIGENESIS
Recent studies of a type of pituitary tumor called adamanti-
nomatous craniopharyngioma (ACP) have revealed a critical
role for mutated PSCs in promoting tumorigenesis through
paracrine activities.
ACPs are aggressive tumors of the sellar region due to
their tendency to inﬁltrate the brain, optic pathways and
nearby vascular structures [67]. Although it can affect adults,
ACP is mostly a pediatric tumor and represents the most com-
mon pituitary tumor in children [68]. Mutations in CTNNB1,
the gene encoding b-catenin, have been identiﬁed in the
majority of ACP samples [69]. These mutations are predicted
to interfere with b-catenin degradation resulting in the accu-
mulation of the protein and the over-activation of the WNT/
b-catenin pathway [70]. Indeed, immunostaining analysis has
revealed the presence of a small population of cells accumu-
lating nucleocytoplasmic b-catenin, the hallmark of pathway
activation, either dispersed throughout the tumor or grouped
forming cell clusters [71]. These clusters are a typical histolog-
ical ﬁnding of human ACP that is not observed in any other
pituitary tumor [72]. Studies in mouse models have provided
important insights into the etiology and pathogenesis of
human ACP.
It has been shown that the expression of a degradation-
resistant form of b-catenin in Rathke’s pouch (RP) precursors
in the mouse (Hesx1Cre/1; Ctnnb1lox(ex3)/1 mouse model) is
sufﬁcient to form tumors that are very similar to human ACP
[73]. RP is the primordium of the anterior pituitary and con-
tain undifferentiated precursors capable of self renew transi-
ently and generate all of the hormone-producing cells of the
anterior pituitary. As the human ACP, mouse tumors contain
nucleocytoplasmic-accumulating cell clusters that activate the
WNT/b-catenin pathway. Moreover, gene proﬁling analysis has
shown cell clusters are likely to represent similar structures in
human and mouse ACP [32].
Human ACPs have not been analyzed for the presence of
CSCs as previously described for human adenoma. Reports
have suggested the presence of stem cell marker expression
in human ACPs [74, 75], but so far no functional characteriza-
tion has been performed. If CSCs exist in these benign
tumors, the mutational landscape seems to be very restricted
as no recurrent mutations have been found in addition to
those in b-catenin. There have been rare cases of malignant
ACP, possibly linked to the use of radiotherapy [76–78]. In
these malignant neoplasms p53 is over-expressed [79], per-
haps indicating that other mutations may have been induced
as the result on the irradiation generating more aggressive
CSCs.
Mouse ACPs, however, have been shown to contain cells
capable of self-propagation and differentiation properties in
vitro [73]. Relative to normal pituitary glands, mouse ACPs
contain up to threefold higher numbers of clonogenic cells
when cultured in stem cell-promoting medium, suggesting an
enlargement of the stem cell compartment in these tumors.
These cells express stemness markers such as Sox2 and Nes-
tin, and show very low levels of expression of differentiation
markers. Moreover, time-lapse microscopy has revealed that
the proliferation rate of clonogenic cells in the tumors is ele-
vated 1.7-fold compared with normal PSCs isolated from con-
trol pituitaries. Whether these clonogenic cells can generate
tumors when transplanted remain to be tested.
Further studies in mice, aiming to understand the role of
PSCs in generation of ACP tumors have been performed.
Expression of oncogenic b-catenin speciﬁcally in SOX21 stem
cells of the adult pituitary (Sox2CreERT2/1;Ctnnb1lox(ex3)/1
mouse model) also results in tumors that are similar to
human ACP [34]. These mouse tumors contain cell clusters
showing nucleocytoplasmic b-catenin and are undifferentiated
(i.e., do not express any hormone), as the human tumors.
This mouse model has been used to trace the descendant
cells of the mutated SOX21 PSCs, a technique referred to as
“genetic tracing” [80]. SOX21 cell are targeted to express
simultaneously oncogenic b-catenin and yellow ﬂuorescent
protein (YFP), the former is the oncogenic stimulus and the
latter allows identiﬁcation of all the daughter cells derived
from the mutated SOX21 PSCs. These experiments have
revealed that the typical cell clusters derive from SOX21 cells,
but intriguingly, the bulk of the tumor mass does not. In
other words, mutated SOX21 cells are not transformed into
CSCs by oncogenic b-catenin; mutated SOX21 PSCs generate
cell clusters that have the capacity to induce tumors in a
paracrine fashion so that the tumor cells are not derived from
SOX21 cells [34] (Fig. 3, paracrine paradigm). Although not
proven, it is possible that the paracrine activities of the clus-
ters induce CSCs, which become the cell-of-origin of the
tumors. In agreement with this notion, cluster cells express a
vast array of growth factors, chemokines and cytokines, and
are acting as signaling centers, possibly changing the tumor
microenvironment and facilitating tumorigenesis [32, 34]. Of
relevance, expression of several cytokines and growth factors
have been shown to play a role in normal pituitary physiology
as well as in pituitary adenoma, a more prevalent pituitary
tumor in humans [40, 81, 82].
BROADER IMPLICATIONS OF THE PARACRINE MODEL OF
TUMORIGENESIS IN THE CANCER FIELD
CSCs carry mutations in oncogenes and tumor supressors,
which are mostly responsible for their tumorigenic behavior.
The identiﬁcation of these mutations in human neoplasms is
of much clinical relevance, as this is the ﬁrst step toward the
Martinez-Barbera, Andoniadou 5
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development of speciﬁc therapies to kill these cells that drive
neoplasia. The better understanding of the early steps that
lead to the generation of CSCs is also relevant, as this may
lead to development of early diagnostic tools that would
allow the treatment of human neoplasms at incipient stages,
possibly where they are more vulnerable to anti-cancer thera-
pies. The pertinent question is what drives the oncogenic
transformation and generation of CSCs?
An excess of growth factors/mitogenic signals may lead to
cell transformation. For instance, by over-activating the same
pathways affected by oncogenic mutations (e.g., b-catenin,
BRAF, KRAS, PATCH1 among others) resulting in increased cell
proliferation, DNA replicative stress, DNA damage, and even-
tually genetic mutations conferring tumorigenic capacity in
transformed cells. Compatible with this notion, the synthesis
and secretion of human TGF-alpha by rat ﬁbroblasts results in
the loss of anchorage-dependent growth in vitro and tumor
formation in nude mice [83]. Similarly, over-expression of
platelet-derived growth factor (PDGF) in neural precursors is
sufﬁcient to induce brain tumors resembling human glioma
[84, 85]; basic ﬁbroblast growth factor (bFGF) [86] can also
transform normal cells resulting in tumors. This may apply to
many more growth factors including EGF, insulin, and hepato-
cyte growth factor (HGF) among others [87].
Genetic evidence in mouse has also shown that tumors/
cancers can develop in a noncell autonomous manner,
whereby the bulk of the tumor mass consists of cells that do
not carry the oncogenic mutations. For instance, conditional
deletion of Notch1 in mouse skin epidermis [88] or hair fol-
licles stem cells [89] leads to overactivation of the WNT/b-cat-
enin pathway and induction of tumors in a noncell
autonomous manner (i.e., the tumor cells are wild type for
Notch1). Additionally, the expression of a constitutively active
form of MEK1, activating the Erk mitogen-activated protein
kinase (MAPK) pathway, in mouse epidermis results in skin
polyps which are mostly formed by wild-type cells for MEK1
[90]. These examples, however, do not demonstrate cellular
transformation or tumor-propagating potential of the cells
that do not carry the oncogenic hit.
Two recent manuscripts have shown that cell transforma-
tion can occur in a paracrine manner in vivo. In a hepatocellu-
lar carcinoma mouse model, it was demonstrated that
deletion of the tumor suppressor gene p53 speciﬁcally in
hepatic stellate cells induces epithelial tumors that are mostly
wild type for p53 [91]. More strikingly, in a mouse model for
leukemia the expression of a degradation resistant form of b-
catenin (i.e., the same used to generate mouse ACP) in osteo-
blast precursors is sufﬁcient to generate oncogenic hemato-
poietic stem cells (HSCs) capable of giving rise to acute
myeloid leukemia (AML). Moreover, transplantation of wild-
type bone-marrow cells to lethality irradiated mice expressing
mutant b-catenin in osteoblasts also results in AML,
Figure 3. Schematic comparing two models of tumor formation: the cancer stem cell and paracrine paradigms. In the cancer stem cell
paradigm (left), a cell, which may be a stem cell, committed or differentiated cell becomes transformed into a cancer stem cell (CSC)
upon exposure to an oncogenic stimulus. This transformed CSC proliferates to give rise to direct derivatives that compose the tumor
mass. In the paracrine paradigm, upon receipt of the oncogenic stimulus the cell becomes secretory. The paracrine signals emanating
from this mutated cell can be perceived by a competent surrounding cell that will become transformed to act like a CSC and become
the cell-of-origin of the tumor. Abbreviation: CSC, cancer stem cell.
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suggesting a critical role of the niche environment in cell
transformation. Furthermore, transplantation of long-term
repopulating HSC progenitors, but not other hematopoietic
populations, can propagate AML when transplanted into wild-
type hosts, indicating that they have become CSCs and do not
require the paracrine activities of the osteoblasts [92].
We think that the studies cited above provide support to
the potential tumor-inducing properties of the b-catenin-
accumulating cluster cells in mouse and human ACP. These
cluster cells express members of the TGF, FGF, and PDGF fami-
lies of growth factors among many others. In addition, the
extracellular matrix (ECM) is also altered around the clusters
[34]. Therefore, cluster cells may be signaling to surrounding
cells either through cell–cell interactions or secreted factors,
with overstimulation of signaling pathways leading to changes
in receptive cells. Circumstantially, actively proliferating cells
stained by Ki67 immunostaining can be detected in close
proximity to the cell clusters [73]. Further research will reveal
the mechanisms whereby cell clusters may induce paracrine
cell transformation and promote tumor growth.
CONCLUSIONS
Murine and human studies have provided support to the idea
that CSCs play a role in pituitary tumorigenesis. Moreover,
analyses of a mouse model for human craniopharyngioma have
revealed that paracrine signaling may be critical in tumour ini-
tiation. It may be argued that paracrinicity is only of relevance
to the understanding of benign tumours. However, once
tumours progress into malignancy, cancer cells may be self-suf-
ﬁcient and able to generate the trophic factors needed for sur-
vival and growth, independent of the initial signals that cause
cell transformation. Even if this latter scenario is real, elucidat-
ing these initial stages of tumorigenesis will provide with a bet-
ter grasp of the pathways that initiate these malignancies. Such
knowledge could translate to the discovery of early diagnostic
biomarkers, which could detect the cancer at incipient stages
of development, when tumour cells are more susceptible to
anti-cancer treatments. Efforts to better characterise and
understand the potential of normal stem cells of the pituitary
gland can only enhance our ability to comprehend their possi-
ble role in pituitary tumour formation and propagation, which
can lead to more effective prognosis and treatments.
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